| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.LUNGCAN.2012.04.011 |
| P698 | PubMed publication ID | 22608141 |
| P50 | author | Nasrollah Erfani | Q41297863 |
| Mohammad Ali Ghayumi | Q79845486 | ||
| Mohammad Reza Haghshenas | Q82496389 | ||
| P2093 | author name string | Abbas Ghaderi | |
| Zahra Mojtahedi | |||
| Davar Amani | |||
| Shayesteh Mofakhami Mehrabadi | |||
| P433 | issue | 2 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| patient | Q181600 | ||
| P304 | page(s) | 306-311 | |
| P577 | publication date | 2012-05-17 | |
| P1433 | published in | Lung Cancer | Q641464 |
| P1476 | title | Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC) | |
| P478 | volume | 77 |
| Q91639484 | A mathematical solution to Peto's paradox using Polya's urn model: implications for the aetiology of cancer in general |
| Q54250692 | A study of circulating anti-CD25 antibodies in non-small cell lung cancer. |
| Q53112790 | Assessment of a novel flow cytometry technique of one-step intracellular staining: example of FOXP3 in clinical samples. |
| Q57151334 | Blood immune cell biomarkers in lung cancer |
| Q36546997 | COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. |
| Q89538337 | Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients |
| Q49778589 | Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer |
| Q86169185 | Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma |
| Q33657979 | Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels |
| Q39022564 | Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy. |
| Q37392642 | Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis |
| Q38684656 | Combination radiotherapy and cantharidin inhibits lung cancer growth through altering tumor infiltrating lymphocytes |
| Q40832649 | Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer |
| Q51410147 | Elevated Regulatory T Cell Levels in Glaucoma Patients in Comparison to Healthy Controls. |
| Q37614743 | Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans. |
| Q28069422 | Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis |
| Q35931188 | Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma |
| Q47830169 | Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors. |
| Q38246950 | Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer |
| Q37601910 | Expression of CTLA-4 and Foxp3 in peripheral blood T cells of patients with squamous cell laryngeal carcinoma |
| Q37639474 | Expression of GARP Is Increased in Tumor-Infiltrating Regulatory T Cells and Is Correlated to Clinicopathology of Lung Cancer Patients |
| Q91829072 | Further Study of Circulating Antibodies to P16, CD25 and FOXP3 in Hepatocellular Carcinoma |
| Q36694379 | Further study of circulating IgG antibodies to CD25-derived peptide antigens in nonsmall cell lung cancer |
| Q38621446 | Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors |
| Q38669273 | Immune Therapy |
| Q45871487 | Immune checkpoint inhibitors in cancer therapy |
| Q26738359 | Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment |
| Q95271900 | Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer |
| Q50048813 | Innate and acquired immune surveillance in the postdissemination phase of metastasis |
| Q34646640 | Intracellular CTLA4 and regulatory T cells in patients with laryngeal squamous cell carcinoma. |
| Q51075813 | Intracellular Flow Cytometry Improvements in Clinical Studies. |
| Q89613150 | Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment |
| Q43184376 | LAP TGF-Beta Subset of CD4(+)CD25(+)CD127(-) Treg Cells is Increased and Overexpresses LAP TGF-Beta in Lung Adenocarcinoma Patients |
| Q52353493 | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. |
| Q38390097 | Mechanisms of immune response regulation in lung cancer |
| Q56891493 | Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention |
| Q38784372 | Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation |
| Q41472493 | Oroxylin A inhibits the generation of Tregs in non-small cell lung cancer |
| Q92382846 | POLR1B is upregulated and promotes cell proliferation in non-small cell lung cancer |
| Q34502899 | Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment |
| Q41092061 | Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy |
| Q36963287 | Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer |
| Q42352636 | Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients |
| Q40978230 | Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine |
| Q38473314 | Regulatory T cells and potential inmmunotherapeutic targets in lung cancer |
| Q57055334 | Roles of the immune system in cancer: from tumor initiation to metastatic progression |
| Q36891539 | Shorter telomere length of T-cells in peripheral blood of patients with lung cancer |
| Q45935803 | Study of circulating antibodies against CD25 and FOXP3 in breast cancer. |
| Q33608606 | The Treg/Th17 paradigm in lung cancer |
| Q92618860 | The expressions and significance of B7-H3 and CTLA-4 in the clinical stages of non-small-cell lung cancer |
| Q38296670 | The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancer |
| Q36283876 | The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis |
| Q41499942 | The role and significance of VEGFR2+ regulatory T cells in tumor immunity |
| Q27024781 | The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention |
| Q28067674 | Trends and advances in tumor immunology and lung cancer immunotherapy |
| Q56895579 | Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer |
| Q89622537 | Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment |
| Q56897146 | Update on immune checkpoint inhibitors in lung cancer |
Search more.